Leerink analyst Thomas Smith initiated coverage of Altimmune with an Outperform rating and $10 price target. Altimunne is an attractive play in an increasingly validated market for MASH therapeutics, and pemvidutide offers a differentiated dual-agonist profile and potential expansion into adjacent serious liver and alcohol-related indications, the analyst tells investors in a research note.
